Page 1

Biogen . BIOGEN REPORTS FIRST QUARTER 2021 RESULTS First quarter revenue $ 2,694 million ; GAAP diluted EPS $ 2.69 ; Non - GAAP diluted EPS $ 5.34 ; 2021 earnings guidance raised Regulatory filings for aducanumab submitted in additional global markets Phase 2 study of BIIB124 ( SAGE - 324 ) in essential tremor met primary endpoint Subcutaneous administration of TYSABRI approved in E.U. Announced collaboration to expand biosimilars pipeline with Phase 3 asset Cambridge , Mass . , April 22 , 2021 -- Biogen Inc. ( Nasdaq : BIIB ) today reported first quarter 2021 financial results . “ Our first quarter 2021 results were consistent with our expectations across MS , SMA , and biosimilars despite increased competition , ” said Michel Vounatsos , Biogen's Chief Executive Officer . “ The launch of VUMERITY has continued to accelerate , providing a valuable new option for patients , and we continue to diligently manage operating expenses . We are pleased with our operational performance during the quarter , and we are increasing our earnings guidance for the full year . " " With an anticipated regulatory decision for aducanumab in the U.S. and a number of exciting pivotal readouts expected this year in depression , choroideremia , and ALS , we continue to believe that 2021 will be a transformative year for Biogen , " Vounatsos said . First Quarter 2021 Financial Results • • First quarter total revenue of $ 2,694 million decreased 24 % versus the prior year at actual currency and decreased 25 % at constant currency * . ○ Multiple sclerosis ( MS ) revenue , including royalties on sales of OCREVUS® , of $ 1,693 million decreased 26 % versus the prior year at both actual and constant currency . ○ ○ SPINRAZAⓇ revenue of $ 521 million decreased 8 % versus the prior year at actual currency and decreased 12 % at constant currency . Biosimilars revenue of $ 205 million decreased 6 % versus the prior year at actual currency and decreased 13 % at constant currency . First quarter GAAP net income and diluted earnings per share ( EPS ) attributable to Biogen Inc. were $ 410 million and $ 2.69 , respectively .